|
[1]
|
D'Angelo, E. and Prat, J. (2010) Uterine Sarcoma: A Review. Gynecologic Oncology, 116, 131-139. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Brown, L. (2008) Pathology of Uterine Malignancies. Clinical Oncology, 20, 433-447. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Leitao, M.M., Sonoda, Y., Brennan, M.F., et al. (2003) Incidence of Lymph Node and Ovarian Metastases in Leiomyosarcoma of the Uterus. Gynecologic Oncology, 91, 209-212. [Google Scholar] [CrossRef]
|
|
[4]
|
Arend, R.C., Toboni, M.D., Montgomery, A.M., et al. (2018) Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm. Oncologist, 23, 1533-1545. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Seagle, B.L., Sobecki-Rausch, J., Strohl, A.E., et al. (2017) Prognosis and Treatment of Uterine Leiomyosarcoma: A National Cancer Database Study. Gynecologic Oncology, 145, 61-70. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Lu, Y.J., Wang, H., Fang, L.Y., et al. (2020) A Nomogram for Predicting Overall Survival in Patients with Uterine Leiomyosarcoma: A SEER Population-Based Study. Future Oncology, 16, 573-584. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Li, D., Yin, N., Du, G.B., et al. (2020) A Real-World Study on Diagnosis and Treatment of Uterine Sarcoma in Western China. International Journal of Biological Sciences, 16, 388-395. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Kapp, D.S., Shin, J.Y. and Chan, J.K. (2008) Prognostic Factors and Survival in 1396 Patients with Uterine Leiomyosarcomas: Emphasis on Impact of Lymphadenectomy and Oophorectomy. Cancer, 112, 820-830. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Zivanovic, O., Jacks, L.M., Iasonos, A., et al. (2012) A Nomogram to Predict Postresection 5-Year Overall Survival for Patients with Uterine Leiomyosarcoma. Cancer, 118, 660-669. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Zivanovic, O., Leitao, M.M., lasonos, A., et al. (2009) Stage-Specific Outcomes of Patients with Uterine Leiomyosarcoma: A Comparison of the International Federation of Gynecology and Obstetrics and American Joint Committee on Cancer Staging Systems. Journal of Clinical Oncology, 27, 2066-2072. [Google Scholar] [CrossRef]
|
|
[11]
|
Takehara, K., Yamashita, N., Watanabe, R., et al. (2020) Clinical Status and Prognostic Factors in Japanese Patients with Uterine Leiomyosarcoma. Gynecologic Oncology, 23, 115-120. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
George, M., Pejovic, M.H. and Kramar, A. (1986) Uterine Sarcoma: Prognostic Factors and Treatment Modalities—Study on 209 Patients. Gynecologic Oncology, 24, 58-67. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Polednak, A.P. (1986) Incidence of Soft-Tissue Cancers in Blacks and Whites in New York State. International Journal of Cancer, 38, 21-26. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Pellenda, A.F., De Bari, B., Deniaud-Alexandre, E., et al. (2017) Outcome and Prognostic Factors in 110 Consecutive Patients with Primary Uterine Leiomyosarcoma: A Rare Cancer Network Study. Chinese Journal of Cancer Research, 29, 521-532. [Google Scholar] [CrossRef] [PubMed]
|